Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) EBITDA Margin (2016 - 2025)

Editas Medicine (EDIT) has disclosed EBITDA Margin for 11 consecutive years, with 325.44% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin rose 10732374.0% to 325.44% in Q3 2025 year-over-year; TTM through Sep 2025 was 428.71%, a 5868.0% decrease, with the full-year FY2024 number at 777.22%, down 56067.0% from a year prior.
  • EBITDA Margin was 325.44% for Q3 2025 at Editas Medicine, up from 1440.58% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 39.91% in Q4 2023 to a low of 136952.38% in Q3 2022.
  • A 5-year average of 15270.03% and a median of 940.09% in 2023 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: tumbled -13631896bps in 2022, then surged 13601229bps in 2023.
  • Editas Medicine's EBITDA Margin stood at 333.71% in 2021, then plummeted by -191bps to 970.72% in 2022, then skyrocketed by 96bps to 39.91% in 2023, then tumbled by -282bps to 152.24% in 2024, then plummeted by -114bps to 325.44% in 2025.
  • Per Business Quant, the three most recent readings for EDIT's EBITDA Margin are 325.44% (Q3 2025), 1440.58% (Q2 2025), and 1635.1% (Q1 2025).